研究実績

2025年

研究No. 執筆者/論文タイトル/掲載誌
TORG1529 Tokito T, Yamada K, Ishii H, et al. : Single-arm multicenter phase II study
on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529). Radiation Oncology 20:2, 2025.
https://doi.org/10.1186/s13014-024-02577-5
TORG1834 Miura S, Tanaka H, Misumi T, et al. : Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834 .Journal of Clinical Oncology 43 (18) : 2049-2058, 2025.
https://ascopubs.org/doi/10.1200/JCO-24-02007
TORG2040 Fukui T, Mamesaya N, Takahashi T, et al. : A Prospective Phase II Trial of First-line Osimertinib for Patients with EGFR Mutation-positive Non-small Cell Lung Cancer and Poor Performance Status (OPEN/TORG2040). Journal of Thoracic Oncology 20 (5): 665-675, 2025.
https://doi.org/10.1016/j.jtho.2024.12.027

2024年

研究No. 執筆者/論文タイトル/掲載誌
TORG1424 Nogami N, Kubo T, Bessho A, et al.: A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL) .Japanese Journal of Clinical Oncology. 54 (7): 805-812, 2024.
https://doi.org/10.1093/jjco/hyae044
TORG1835 Ikeda S, Ogura T, Kato T, et al. Nintedanib plus chemotherapy for small cell lung cancer with comorbid Idiopathic pulmonary fibrosis. Annals of the American Thoracic Society 21 (4) : 635-643, 2024.
https://doi.org/10.1513/AnnalsATS.202311-941OC
TORG1937 Nakamichi S, Kubota K, Misumi T, et al.: Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non-small-cell lung cancer: TORG1937 (DATE study). Clinical Cancer Research 30 (6) : 1104-1110, 2024.
https://doi.org/10.1158/1078-0432.CCR-23-2568
TG2101
Osi-risk
Nishioka N, Endo M, Notsu A, et al.: Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101) . Targeted Oncology 19: 423-433, 2024.
https://doi.org/10.1007/s11523-024-01048-x

2023年

研究No. 執筆者/論文タイトル/掲載誌
TORG0503
(QOL)
Matsuda A, Yamaoka K, Kunitoh H, et al.: Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503. Quality of Life Research 32: 2629-2637, 2023
https://doi.org/10.1007/s11136-023-03424-y
TORG1321 Kasai T, Mori K, Nakamura Y, et al.: Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321. Cancer Medicine 12 (14): 14988-14999, 2023
https://doi.org/10.1002/cam4.6135
TORG1426 Ichikawa Y, Seki N, Honda T, et al.: Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426. Translational Cancer Research 12 (4): 873-886, 2023
https://dx.doi.org/10.21037/tcr-22-2144
JCOG1201/
TORG1528
Shimokawa T, Okamoto H, Machida R,et al.: Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.
Lung Cancer 181:107195, 2023
https://doi.org/10.1016/j.lungcan.2023.107195
TORG1938 Okuma Y, Nomura S, Ninomiya K, et al.: Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study). Future Oncol 19: 1515-1521, 2023
https://doi.org/10.2217/fon-2022-1128
TORG2241 Nakamichi S, Kubota K, Matsuyama K, et al.: A Phase II Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q). Clin Lung Cancer 25 (1): 85-90, 2024
https://doi.org/10.1016/j.cllc.2023.09.006

2022年

研究No. 執筆者/論文タイトル/掲載誌
TORG1018
related article
Taniguchi Y, Okamoto H, Shimokawa T, et al.: Concurrent chemoradiotherapy with cisplatin+S-1 versus cisplatin+other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data. BMC Pulmonary Medicine 22: 31-42, 2022
TORG1630 Taniguchi Y, Shimokawa T, Takiguchi Y et al.: A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naive non-small-cell lung cancer: TORG1630. Clinical Cancer Research 22: 4402-4409, 2022
doi.org/10.1158/1078-0432.ccr-22-1687
TORG1936 Ikeda S, Kato T, Kenmotsu H, et al.: Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study. The Oncologist 27: 720-e702, 2022
doi: 10.1093/oncolo/oyac118
TORG1936
related article
Ikeda S, Misumi T, Kato T, et al.: Immune Checkpoint Inhibitor-Induced Pneumonitis in Patients With Non-Small Cell Lung Cancer and Preexisting Interstitial Lung Diseases Really Mild and Easily Manageable? CHEST 162: E65-E66, 2022. doi: 10.1016/j.chest.2022.02.057
TORG2040 Fukui T, Sasaki J, Igawa S, et al.: Rationale and protocol design of a phase II study of frst-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040). BMC Cancer 22: 1314, 2022
https://doi.org/10.1186/s12885-022-10409-6

2021年

研究No. 執筆者/論文タイトル/掲載誌
TORG1018 Shimokawa T, Yamada K, Tanaka H, et al.: Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer. Cancer Medicine 10: 626-633, 2021
TORG1632 Noro R, Igawa S, Bessho A, et al.: A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632. Lung Cancer 161: 49-54, 2021
TORG1936
related article
Ikeda S, Kato T, Kenmotsu H, et al.Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. European Journal of Cancer 151: 249-251, 2021 (Letter to the Editor) doi.org/10.1016/j.ejca.2021.03.050

2020年

研究No. 執筆者/論文タイトル/掲載誌
TORG0503 Kubota K, Kunitoh H, Seto T, et al.: Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503. Lung Cancer 141: 32-36, 2020
TORG0808
TORG0913
Nakahara Y, Shimokawa T, Misumi Y, et al.: Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913. Investigational New Drugs (published online 15 Aug 2020) doi: 10.1007/s10637-020-00985-4
TORG1320 Otani S, Sasaki J, Nakahara Y, et al.: Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320). Investigational New Drugs (published online 07 Nov 2020) doi: 10.1007/s10637-020-01031-z
TORG1322 Zenke Y, Niho S, Umemura S, et al.: Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged ≥75 years with squamous-cell lung cancer: TORG1322. Lung Cancer 146 (8): 182-188, 2020. doi:10.1016/j.lungcan.2020.05.005
TORG1323 Kozuki T, Nogami N, Hataji O, et al.: Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. Translational Lung Cancer Research 9 (3) : 459-470, 2020. doi: 10.21037/tlcr.2020.03.29
TORG1425 Miyamoto S, Azuma K, Ishii H, et al.: Low-dose erlotinib treatment in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer: A multicenter Phase 2 trial. JAMA Oncology 6 (7): e201250. doi: 10.1001/jamaoncol.2020.1250
TORG1834 Miura S, Yamanaka T, Kato T, et al.: Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834). Clinical Lung Cancer 21 (6): e592-e596. doi: 10.1016/j.cllc.2020.05.011
TORG1835 Ikeda S, Ogura T, Kato T, et al.: Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis. Therapeutic Advances in Medical Oncology 12: 1-6, 2020. doi: 10.1177/1758835920923431
TORG1936 Ikeda S, Kato T, Kenmotsu H, et al. A phase II study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonias. Journal of Thoracic Oncology 15: 1935-1942, 2020. doi: 10.1016/j.jtho.2020.08.018
Ikeda S, Kato T, Kenmotsu H, et al.: A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study. Therapeutic Advances in Medical Oncology 12: 1-6, 2020. doi: 10.1177/1758835920922022

2019年

研究No. 執筆者/論文タイトル/掲載誌
TORG1017 Nakahara Y, Hosomi Y, Shibuya M, et al.: Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017. Molecular and Clinical Oncology 11: 349-353, 2019

2018年

研究No. 執筆者/論文タイトル/掲載誌
TORG0809 Niho S, Ikeda N, Michimae H, et al.Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer: Thoracic Oncology Research Group (TORG) 0809. American Journal of Clinical Oncology 41: 1113-1117, 2018. doi: 10.1097/COC.0000000000000438
TORG1016 Ikeda S, Kato T, Ogura T, et al.: Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016. BMC Cancer 18: 241, 2018

2017年

研究No. 執筆者/論文タイトル/掲載誌
TORG0604 Misumi Y, Okamoto H, Sasaki J, et al.: Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604. BMC Cancer 17: 377, 2017

2016年

研究No. 執筆者/論文タイトル/掲載誌
TORG0912 Takayama K, Atagi S, Imamura F, et al.: Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients?Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study. Support Care Cancer 24 (8): 3473-3480, 2016
TORG1015 Kozuki T, Nogami N, Kitajima H, et al.: Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non- small cell lung cancer in elderly patients: TORG1015. BMC Cancer 16: 306, 2016

2015年

研究No. 執筆者/論文タイトル/掲載誌
TORG0910 Yamada K, Saito H, Kondo T, et al.: Multicenter phase II study of nedaplatin and irinotecan for patients with squamous cell carcinoma of the lung: Thoracic Oncology Research Group 0910. Anticancer Research 35 (12): 6705-6711, 2015
TORG0911 Yamada K, Aono H, Hosomi Y, et al.: A prospective, multicenter phase II trial of low-dose erlotinib monotherapy for patients with previously treated non-small cell lung cancer with EGFR mutations: Thoracic Oncology Research Group 0911. European Journal of Cancer 51 (14) : 1904-1910, 2015
TORG1014 Takagi Y, Hosomi Y, Oshita F, et al.: Feasibility study of docetaxel plus bevacizumab therapy for elderly patients with non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 1014. BMC Cancer 15: 740, 2015

2014年

研究No. 執筆者/論文タイトル/掲載誌
TORG1016 Ikeda S, Sekine A, Kato T, et al.: Diffuse alveolar hemorrhage as a fatal adverse effect of bevacizumab: an autopsy case. Japanese Journal of Clinical Oncology 44 (5) : 497-500, 2014

2013年

研究No. 執筆者/論文タイトル/掲載誌
TORG0809 Niho S, Ikeda N, Michimae H, et al.: Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0809. British Journal of Cancer 109 (3) : 545-551, 2013

2011年

研究No. 執筆者/論文タイトル/掲載誌
TORG0705 Takiguchi Y, Seto T, Ichinose Y, et al.: Long-Term Administration of Second-Line Chemotherapy with S-1 and Gemcitabine for Platinum-Resistant Non-small Cell Lung Cancer A Phase II Study. Journal of Thoracic Oncology 6 (1) : 156-160, 2011

2010年

研究No. 執筆者/論文タイトル/掲載誌
TORG0502 Seto T, Yamanaka T, Wasada I, et al.: Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502. Lung Cancer 69 (2) : 213-217, 2010

2006年

研究No. 執筆者/論文タイトル/掲載誌
TORG0301 Onoda S, Masuda N, Seto T, et al.: Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301. Journal of Clinical Oncology 24 (34) : 5448-5453, 2006


ページトップへ